Oxford Ledge
Search
No licensed closing price on file for SGMT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 15:03 UTC.
The company is a clinical-stage biopharmaceutical firm developing fatty acid synthase (FASN) inhibitors to treat diseases linked to palmitate overproduction. Its lead candidate, denifanstat, is an oral once-daily drug being tested for metabolic dysfunction-associated steatohepatitis (MASH), acne, and certain cancers, while a second inhibitor, TVB-3567, targets acne. In a Phase 2b trial, denifanstat met primary endpoints in patients with advanced liver fibrosis and demonstrated anti-fibrotic activity with a generally tolerable safety profile.
Summarized from Sagimet Biosciences Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | -30.61% |
The company is a clinical-stage biopharmaceutical firm developing fatty acid synthase (FASN) inhibitors to treat diseases linked to palmitate overproduction.
Sagimet Biosciences Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 15:03 UTC. This page is also available as JSON at /api/data?ticker=SGMT and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for SGMT and 5,000+ tickers.
Create a free account — keep SGMTGET /api/data?ticker=SGMT
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt